|
Volumn 23, Issue 2-3, 2000, Pages 535-542
|
In-use testing of extemporaneously prepared suspensions of second generation non-nucleoside reversed transcriptase inhibitors in support of Phase I clinical studies
a a a a a a a |
Author keywords
Dissolution; HPLC; NNRTI; Suspension
|
Indexed keywords
4 CYCLOPROPYLETHYNYL 5,6 DIFLUORO 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE;
6 CHLORO 4 CYCLOPROPYLETHYNYL 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE;
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
ORA PLUS;
ORA SWEET;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
UNCLASSIFIED DRUG;
ARTICLE;
DISSOLUTION;
DRUG DETERMINATION;
DRUG STABILITY;
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;
LIQUID LIQUID EXTRACTION;
PARTICLE SIZE;
POWDER;
PRIORITY JOURNAL;
SUSPENSION;
TECHNIQUE;
ANTI-HIV AGENTS;
CHROMATOGRAPHY, HIGH PRESSURE LIQUID;
CLINICAL TRIALS, PHASE I;
PHARMACEUTICAL PREPARATIONS;
QUINAZOLINES;
QUINAZOLINONES;
QUINOLONES;
REVERSE TRANSCRIPTASE INHIBITORS;
SOLUBILITY;
SPECTROPHOTOMETRY, ULTRAVIOLET;
|
EID: 0034663889
PISSN: 07317085
EISSN: None
Source Type: Journal
DOI: 10.1016/S0731-7085(00)00337-X Document Type: Article |
Times cited : (4)
|
References (6)
|